IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v17y2020i10p3664-d361875.html
   My bibliography  Save this article

Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis

Author

Listed:
  • Maria Mirabelli

    (Department of Health Sciences, University “Magna Graecia” of Catanzaro, Viale Europa, 88100 Catanzaro, Italy
    These authors contribute equally to this work.)

  • Eusebio Chiefari

    (Department of Health Sciences, University “Magna Graecia” of Catanzaro, Viale Europa, 88100 Catanzaro, Italy
    These authors contribute equally to this work.)

  • Luigi Puccio

    (Complex Operative Unit of Endocrinology and Diabetes, Hospital Pugliese-Ciaccio, 88100 Catanzaro, Italy)

  • Daniela Patrizia Foti

    (Department of Health Sciences, University “Magna Graecia” of Catanzaro, Viale Europa, 88100 Catanzaro, Italy)

  • Antonio Brunetti

    (Department of Health Sciences, University “Magna Graecia” of Catanzaro, Viale Europa, 88100 Catanzaro, Italy)

Abstract

Patients with diabetes have been reported to have enhanced susceptibility to severe or fatal COVID-19 infections, including a high risk of being admitted to intensive care units with respiratory failure and septic complications. Given the global prevalence of diabetes, affecting over 450 million people worldwide and still on the rise, the emerging COVID-19 crisis poses a serious threat to an extremely large vulnerable population. However, the broad heterogeneity and complexity of this dysmetabolic condition, with reference to etiologic mechanisms, degree of glycemic derangement and comorbid associations, along with the extensive sexual dimorphism in immune responses, can hamper any patient generalization. Even more relevant, and irrespective of glucose-lowering activities, DPP4 inhibitors and GLP1 receptor agonists may have a favorable impact on the modulation of viral entry and overproduction of inflammatory cytokines during COVID-19 infection, although current evidence is limited and not univocal. Conversely, SGLT2 inhibitors may increase the likelihood of COVID-19-related ketoacidosis decompensation among patients with severe insulin deficiency. Mindful of their widespread popularity in the management of diabetes, addressing potential benefits and harms of novel antidiabetic drugs to clinical prognosis at the time of a COVID-19 pandemic deserves careful consideration.

Suggested Citation

  • Maria Mirabelli & Eusebio Chiefari & Luigi Puccio & Daniela Patrizia Foti & Antonio Brunetti, 2020. "Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis," IJERPH, MDPI, vol. 17(10), pages 1-12, May.
    • Handle: RePEc:gam:jijerp:v:17:y:2020:i:10:p:3664-:d:361875
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/17/10/3664/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/17/10/3664/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. V. Stalin Raj & Huihui Mou & Saskia L. Smits & Dick H. W. Dekkers & Marcel A. Müller & Ronald Dijkman & Doreen Muth & Jeroen A. A. Demmers & Ali Zaki & Ron A. M. Fouchier & Volker Thiel & Christian Dr, 2013. "Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC," Nature, Nature, vol. 495(7440), pages 251-254, March.
    2. Konstantinos Makrilakis, 2019. "The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect," IJERPH, MDPI, vol. 16(15), pages 1-20, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Milad Haghani & Pegah Varamini, 2021. "Temporal evolution, most influential studies and sleeping beauties of the coronavirus literature," Scientometrics, Springer;Akadémiai Kiadó, vol. 126(8), pages 7005-7050, August.
    2. Weiwei Ji & Qi Peng & Xueqiong Fang & Zehou Li & Yaxin Li & Cunfa Xu & Shuqing Zhao & Jizong Li & Rong Chen & Guoxiang Mo & Zhanyong Wei & Ying Xu & Bin Li & Shuijun Zhang, 2022. "Structures of a deltacoronavirus spike protein bound to porcine and human receptors," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    3. Shubhadeep Roychoudhury & Anandan Das & Pallav Sengupta & Sulagna Dutta & Shatabhisha Roychoudhury & Arun Paul Choudhury & A. B. Fuzayel Ahmed & Saumendra Bhattacharjee & Petr Slama, 2020. "Viral Pandemics of the Last Four Decades: Pathophysiology, Health Impacts and Perspectives," IJERPH, MDPI, vol. 17(24), pages 1-39, December.
    4. Hossein Hozhabri & Francesca Piceci Sparascio & Hamidreza Sohrabi & Leila Mousavifar & René Roy & Daniela Scribano & Alessandro De Luca & Cecilia Ambrosi & Meysam Sarshar, 2020. "The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting," IJERPH, MDPI, vol. 17(16), pages 1-35, August.
    5. Muhammad Azher Hassan & Tariq Mehmood & Ehtisham Lodhi & Muhammad Bilal & Afzal Ahmed Dar & Junjie Liu, 2022. "Lockdown Amid COVID-19 Ascendancy over Ambient Particulate Matter Pollution Anomaly," IJERPH, MDPI, vol. 19(20), pages 1-31, October.
    6. Magen E. Francis & Ethan B. Jansen & Anthony Yourkowski & Alaa Selim & Cynthia L. Swan & Brian K. MacPhee & Brittany Thivierge & Rachelle Buchanan & Kerry J. Lavender & Joseph Darbellay & Matthew B. R, 2023. "Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2," Nature Communications, Nature, vol. 14(1), pages 1-21, December.
    7. Mohamed A. Farrag & Haitham M. Amer & Rauf Bhat & Maaweya E. Hamed & Ibrahim M. Aziz & Ayman Mubarak & Turki M Dawoud & Sami G Almalki & Fayez Alghofaili & Ahmad K. Alnemare & Raid Saleem Al-Baradi & , 2021. "SARS-CoV-2: An Overview of Virus Genetics, Transmission, and Immunopathogenesis," IJERPH, MDPI, vol. 18(12), pages 1-14, June.
    8. Yan Yang & Zixin Cai & Jingjing Zhang, 2021. "DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis," PLOS ONE, Public Library of Science, vol. 16(5), pages 1-10, May.
    9. Luo-Yuan Xia & Zhen-Fei Wang & Xiao-Ming Cui & Yuan-Guo Li & Run-Ze Ye & Dai-Yun Zhu & Fang-Xu Li & Jie Zhang & Wen-Hao Wang & Ming-Zhu Zhang & Wan-Ying Gao & Lian-Feng Li & Teng-Cheng Que & Tie-Cheng, 2024. "Isolation and characterization of a pangolin-borne HKU4-related coronavirus that potentially infects human-DPP4-transgenic mice," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    10. Tuersunjiang Keyoumu & Wanbiao Ma & Ke Guo, 2023. "Global Stability of a MERS-CoV Infection Model with CTL Immune Response and Intracellular Delay," Mathematics, MDPI, vol. 11(4), pages 1-26, February.
    11. Chunyan Wang & Emma L. Hesketh & Tatiana M. Shamorkina & Wentao Li & Peter J. Franken & Dubravka Drabek & Rien Haperen & Sarah Townend & Frank J. M. Kuppeveld & Frank Grosveld & Neil A. Ranson & Joost, 2022. "Antigenic structure of the human coronavirus OC43 spike reveals exposed and occluded neutralizing epitopes," Nature Communications, Nature, vol. 13(1), pages 1-15, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:17:y:2020:i:10:p:3664-:d:361875. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.